{"id":8826,"date":"2026-09-30T14:18:24","date_gmt":"2026-09-30T11:18:24","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8826"},"modified":"2026-09-30T14:18:27","modified_gmt":"2026-09-30T11:18:27","slug":"satellos-forazapadin-phase-2-trial","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-forazapadin-phase-2-trial\/","title":{"rendered":"Satellos, Duchenne Musk\u00fcler Distrofisi \u0130\u00e7in Forazapadin&#039;in Faz 2 \u00c7al\u0131\u015fmas\u0131nda Hasta Kay\u0131tlar\u0131n\u0131 Tamamlad\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Satellos Bioscience, Duchenne kas distrofisi (DMD) olan erkek \u00e7ocuklarda Forazapadin&#039;i (SAT-3247) de\u011ferlendiren Faz 2 klinik \u00e7al\u0131\u015fmas\u0131 BASECAMP&#039;e kay\u0131tlar\u0131n tamamland\u0131\u011f\u0131n\u0131 duyurdu.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Forazapadin, DMD ve di\u011fer dejeneratif kas hastal\u0131klar\u0131 olan ki\u015filerde kas yenilenmesini sa\u011flamak amac\u0131yla geli\u015ftirilen, a\u011f\u0131zdan al\u0131nan k\u00fc\u00e7\u00fck molek\u00fcll\u00fc bir ila\u00e7 aday\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>BASECAMP \u00e7al\u0131\u015fmas\u0131na 7 ila 10 ya\u015f aras\u0131 y\u00fcr\u00fcyebilen erkek \u00e7ocuklar dahil edildi. Kat\u0131l\u0131mc\u0131lar Amerika Birle\u015fik Devletleri, Kanada, Avustralya, Bel\u00e7ika, \u0130spanya, Polonya ve S\u0131rbistan&#039;daki 18 klinik merkezden se\u00e7ildi.<\/strong> \u015eirket, ilk kat\u0131l\u0131mc\u0131n\u0131n taramas\u0131n\u0131 yapt\u0131ktan sonraki dokuz aydan k\u0131sa bir s\u00fcre i\u00e7inde kay\u0131t hedefine ula\u015ft\u0131\u011f\u0131n\u0131 ve hatta bu hedefi a\u015ft\u0131\u011f\u0131n\u0131 bildirdi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kat\u0131l\u0131mc\u0131lar, e\u015fit gruplar halinde rastgele olarak 60 mg Forazapadin, 120 mg Forazapadin veya plasebo alacak \u015fekilde gruplara ayr\u0131ld\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7al\u0131\u015fma, 12 haftal\u0131k plasebo kontroll\u00fc bir d\u00f6nemi ve ard\u0131ndan 36 haftal\u0131k randomize aktif tedavi d\u00f6nemini i\u00e7ermektedir. Birincil de\u011ferlendirme noktalar\u0131, dinamometre kullan\u0131larak \u00f6l\u00e7\u00fclen g\u00fcvenlik, tolere edilebilirlik ve kas kuvvetindeki de\u011fi\u015fikliklere odaklanmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130kincil de\u011ferlendirmeler, Forazapadin&#039;in kas kalitesi, fiziksel fonksiyon ve kas yenilenmesi \u00fczerindeki potansiyel etkilerini incelemek \u00fczere tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos&#039;ye g\u00f6re, \u00e7al\u0131\u015fma birden fazla doz grubunun yan\u0131 s\u0131ra klinik, fonksiyonel ve biyomarker de\u011ferlendirmelerini de i\u00e7eriyor. \u015eirket, \u00e7al\u0131\u015fman\u0131n Forazapadin ve Duchenne kas distrofisi tedavisindeki potansiyel rol\u00fc hakk\u0131nda ek bilgiler sa\u011flayaca\u011f\u0131n\u0131 \u00f6ng\u00f6r\u00fcyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos ayr\u0131ca \u00f6nceki veri yay\u0131nlama zaman \u00e7izelgesinde bir de\u011fi\u015fiklik yap\u0131ld\u0131\u011f\u0131n\u0131 duyurdu. <strong>\u015eirket, daha \u00f6nce planland\u0131\u011f\u0131 gibi \u00f6zet sonu\u00e7lar\u0131 daha erken yay\u0131nlamak yerine, BASECAMP&#039;ten elde edilen \u00f6zet klinik verileri 2027&#039;nin ilk \u00e7eyre\u011finde payla\u015fmay\u0131 bekliyor.<\/strong> \u015eirket, sonu\u00e7lar\u0131 a\u00e7\u0131klamadan \u00f6nce eksiksiz bir veri seti olu\u015fturmak i\u00e7in ek s\u00fcreye ihtiya\u00e7 duydu\u011funu belirtti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kay\u0131t i\u015flemlerinin tamamlanmas\u0131, Forazapadin&#039;in klinik geli\u015fiminde \u00f6nemli bir a\u015famay\u0131 i\u015faret etmektedir. BASECAMP program\u0131 i\u00e7in bir sonraki \u00f6nemli d\u00f6n\u00fcm noktas\u0131, \u015fu anda 2027&#039;nin ilk \u00e7eyre\u011finde beklenilen, en son klinik verilerin yay\u0131nlanmas\u0131 olacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha Fazlas\u0131n\u0131 Ke\u015ffedin<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/map\/\" target=\"_blank\" rel=\"noopener\">Duchenne Klinik Ara\u015ft\u0131rma Yerleri Haritas\u0131<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience has announced the completion of enrollment in BASECAMP, a Phase 2 clinical trial evaluating Forazapadin (SAT-3247) in boys with Duchenne muscular dystrophy (DMD). Forazapadin is an orally administered small-molecule drug candidate being developed to restore muscle regeneration in people living with DMD and other degenerative muscle diseases. The BASECAMP trial enrolled ambulatory boys [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":8827,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[922,137,903,914,251,252,253],"class_list":["post-8826","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-basecamp","tag-clinical-trial","tag-forazapadin","tag-phase-2","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"subtitle":"Satellos, Duchenne kas distrofisi i\u00e7in Forazapadin'in (SAT-3247) Faz 2 BASECAMP \u00e7al\u0131\u015fmas\u0131nda hasta kayd\u0131n\u0131 tamamlad\u0131 ve \u00f6n sonu\u00e7lar\u0131n 2027'nin ilk \u00e7eyre\u011finde a\u00e7\u0131klanmas\u0131 bekleniyor.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8826"}],"version-history":[{"count":1,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8826\/revisions"}],"predecessor-version":[{"id":8828,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8826\/revisions\/8828"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8827"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}